MENU
+Compare
EVO
Stock ticker: NASDAQ
AS OF
Sep 26 closing price
Price
$3.48
Change
-$0.06 (-1.69%)
Capitalization
1.23B

EVO Evotec SE Forecast, Technical & Fundamental Analysis

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations... Show more

EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EVO with price predictions
Sep 26, 2025

EVO's RSI Indicator recovers from oversold territory

The RSI Oscillator for EVO moved out of oversold territory on September 05, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 15, 2025. You may want to consider a long position or call options on EVO as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EVO just turned positive on September 08, 2025. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where EVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EVO broke above its upper Bollinger Band on September 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EVO entered a downward trend on September 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.245) is normal, around the industry mean (16.941). P/E Ratio (0.000) is within average values for comparable stocks, (73.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.959). EVO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.353) is also within normal values, averaging (45.936).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EVO is expected to report earnings to fall 65.85% to -4 cents per share on November 05

Evotec SE EVO Stock Earnings Reports
Q3'25
Est.
$-0.05
Q2'25
Missed
by $0.08
Q1'25
Missed
by $0.09
Q4'24
Missed
by $0.09
Q3'24
Est.
$-0.12
The last earnings report on August 13 showed earnings per share of -14 cents, missing the estimate of -6 cents. With 14.10K shares outstanding, the current market capitalization sits at 1.23B.
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Essener Bogen 7
Phone
+49 40560810
Employees
4952
Web
https://www.evotec.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TGRYX12.430.09
+0.73%
TCW Global Real Estate N
TFIFX48.750.35
+0.72%
T. Rowe Price Financial Services I
PQSAX24.930.17
+0.69%
Virtus KAR Small-Cap Value A
STCZX18.100.06
+0.33%
Virtus Silvant Large-Cap Growth Stk R6
FFCMX22.180.07
+0.32%
Fidelity Advisor Asset Manager 50% C

EVO and Stocks

Correlation & Price change

A.I.dvisor tells us that EVO and ACB have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVO and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-1.69%
ACB - EVO
29%
Poorly correlated
-1.82%
OGI - EVO
27%
Poorly correlated
-3.43%
CGC - EVO
24%
Poorly correlated
-2.19%
TAK - EVO
23%
Poorly correlated
+0.61%
ELAN - EVO
22%
Poorly correlated
+3.65%
More

Groups containing EVO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-1.69%
Pharmaceuticals: Generic
industry (224 stocks)
14%
Poorly correlated
+0.11%